GMP News and Research

RSS
FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

SeraCare Life Sciences inks CRADA with NCI to create positive controls for cancer assays

SeraCare Life Sciences inks CRADA with NCI to create positive controls for cancer assays

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

IDT’s fully licensed MGB Eclipse qPCR probes available for online ordering

IDT’s fully licensed MGB Eclipse qPCR probes available for online ordering

TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell’s pilot manufacturing facility activities put on temporary partial hold

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

New finding may lead to development of immunity-based therapies for tuberculosis

New finding may lead to development of immunity-based therapies for tuberculosis

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

SCI Logistics announces official opening of new healthcare-dedicated facility in Canada

SCI Logistics announces official opening of new healthcare-dedicated facility in Canada

China Pharma revenue decreases 20% to $5.7 million in Q1 2015

China Pharma revenue decreases 20% to $5.7 million in Q1 2015

JHL Biotech closes $45.6 million Series C round of financing

JHL Biotech closes $45.6 million Series C round of financing

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Full range of Lab M media for detection and isolation of Listeria shown together for the first time

Full range of Lab M media for detection and isolation of Listeria shown together for the first time

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.